Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

CONCLUSIONS: Inclisiran treatment did not reduce LDL-C levels in patients with homozygous familial hypercholesterolemia despite substantial lowering of PCSK9 levels. Inclisiran was well-tolerated, and the safety findings were consistent with previously reported studies and the overall safety profile.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT03851705.PMID:37850379 | DOI:10.1161/CIRCULATIONAHA.122.063460

Source: Circulation - October 18, 2023 Category: Cardiology Authors: Frederick Raal Ronen Durst Ran Bi Zsolt Talloczy Pierre Maheux Anastasia Lesogor John J P Kastelein ORION-5 Study Investigators Source Type: research